Document Detail

Cladribine treatment of a patient with hairy cell leukemia and concomitant multiple sclerosis.
MedLine Citation:
PMID:  10529514     Owner:  NLM     Status:  MEDLINE    
This is the first report on a patient suffering from both multiple sclerosis (MS) and hairy cell leukemia. The patient was first treated with interferon-alpha. Due to disease progression two courses of cladribine were given resulting in an improvement of the clinical course of both diseases. Interestingly, it was possible to arrest and even ameliorate the progression of MS by administering as little as 30% of the dosage recently recommended for the treatment of this disease.
W Hilbe; T Berger; G Konwalinka; J Thaler
Related Documents :
16420394 - A recommended treatment algorithm in relapsing multiple sclerosis: report of an interna...
18573824 - Impact of disease-modifying treatments in north african migrants with multiple sclerosi...
7931434 - Hla and prognosis in multiple sclerosis.
8437024 - Presence of t-cell subset abnormalities in newly diagnosed cases of multiple sclerosis ...
3415404 - Clinical predictors of electrophysiologic findings in patients with syncope of unknown ...
22989794 - Resolution of cervical syringomyelia after transoral odontoidectomy and occipitocervica...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Acta haematologica     Volume:  102     ISSN:  0001-5792     ISO Abbreviation:  Acta Haematol.     Publication Date:  1999  
Date Detail:
Created Date:  1999-12-08     Completed Date:  1999-12-08     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0141053     Medline TA:  Acta Haematol     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  99-100     Citation Subset:  IM    
Department of Internal Medicine, University of Innsbruck, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use*
Cladribine / therapeutic use*
Disease Progression
Leukemia, Hairy Cell / complications,  drug therapy*
Middle Aged
Multiple Sclerosis / complications*
Reg. No./Substance:
0/Antineoplastic Agents; 4291-63-8/Cladribine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Rituximab (anti-CD20 monoclonal antibody) administration in a young patient with resistant B-prolymp...
Next Document:  Homozygous prothrombin gene mutation and ischemic cerebrovascular disease: a case report.